Alkermes Public Limited Company

Case Details

Class Period:
February 17, 2017 – November 1, 2018
Date Filed:
December 27, 2018
Case Number:
1:18-cv-07410
Jurisdiction:
Eastern District of New York

Case Summary

According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the U.S. Food and Drug Administration ("FDA") had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Action Details

View Complaint (pdf)

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us.